Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN107,9108,2-1,92
Msft-0,13
Nokia5,8665,921,16
IBM1,10
Mercedes-Benz Group AG57,5857,60,89
PFE0,40
14.02.2026 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 13.02.2026 21:59:57
Twist Bioscience Rg (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (USD)
49,06 2,77 1,32 29 082 122
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 15.02.2026
Popis společnosti
Obecné informace
Název společnostiTwist Bioscience Corp
TickerTWST
Kmenové akcie:Ordinary Shares
RICTWST.O
ISIN-
Poslední známé roční výsledky30.09.2025
Poslední známé čtvrtletní výsledky31.12.2025
Počet zaměstnanců k 30.09.2025 979
Akcie v oběhu k 27.01.2026 61 311 704
MěnaUSD
Kontaktní informace
Ulice681 Gateway Blvd.
MěstoSOUTH SAN FRANCISCO
PSČ94080
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon18 007 190 671
Fax13025313150

Business Summary: Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.
Financial Summary: BRIEF: For the three months ended 31 December 2025, Twist Bioscience Corp revenues increased 17% to $103.7M. Net loss decreased 3% to $30.5M. Revenues reflect DNA synthesis and protein solutions segment increase of 27% to $51.1M, NGS applications segment increase of 8% to $52.6M, EMEA segment increase of 36% to $38.4M, Americas segment increase of 9% to $58.4M. Lower net loss reflects Research and development - Balancing decrease of 16% to $15.5M (expense).
Odvětvová klasifikace
TRBC2012Biopharmaceuticals
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS1997Biological Product (except Diagnostic) Manufacturing
SICBiological Prod's Not Diagnostic
SICCommercial Physical Research



  • Poslední aktualizace: 15.02.2026
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive OfficerEmily Leproust5225.10.2022
President, Chief Operating OfficerPatrick Finn5425.10.2022
Chief Financial OfficerAdam Laponis4908.01.202408.01.2024
Senior Vice President - Human ResourcesPaula Green58
Chief Accounting Officer, Vice PresidentRobert Werner52
Chief Legal Officer and Corporate SecretaryDennis Cho5401.02.202427.09.2021